Drug
Navitoclax clinical trials
Also written ABT-263 and A-855071.0.
- studies test it
- 38
- open now
- 1
- in phase 3
- 2
- first study started
- 2006
Keep track of what changes. Save the navitoclax studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- ABT-263
- 33
Studies by the year they started
38 studies that test it; most in 2009 (8)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 8 |
| 2010 | 4 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 29
- Phase 2
- 15
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 24 · Other 14
AbbVie (12) · National Cancer Institute (NCI) (6) · AbbVie (prior sponsor, Abbott) (5) · Abbott (5) · Genentech, Inc. (2) · City of Hope Medical Center (1) · Jacqueline Garcia, MD (1) · Sunnybrook Health Sciences Centre (1)
Often tested with
Tested in the same studies.
Venetoclax (7) · Ruxolitinib (4) · Decitabine (3) · Rituximab (2) · Trametinib (1) · Olaparib (1) · Sorafenib (1) · Osimertinib (1)
Studies
Open first, then newest update. How each study uses navitoclax is read from its arms, and is right about nine times in ten.
Testing it · 38
- A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALLNot yet recruitingPhase 1/2Israeli Medical AssociationNCT05054465Written as Navitoclax
- Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With VenetoclaxActive, not recruitingPhase 1City of Hope Medical CenterNCT05222984Written as Navitoclax
- Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT02079740Written as Navitoclax
- Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant MelanomaActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT01989585Written as Navitoclax
- Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic SyndromeCompletedPhase 1Thomas Jefferson UniversityNCT05564650Written as Navitoclax
- Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With MyelofibrosisCompletedPhase 3AbbVieNCT04472598Written as Navitoclax
- Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid NeoplasmsActive, not recruitingPhase 1Jacqueline Garcia, MDNCT05455294Written as Navitoclax
- Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory MyelofibrosisActive, not recruitingPhase 3AbbVieNCT04468984Written as Navitoclax
- Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With MyelofibrosisActive, not recruitingPhase 1AbbVieNCT04454658Written as Navitoclax
- Safety Study of ABT-263 in Combination With Rituximab in Lymphoid CancersCompletedPhase 1AbbVieNCT00788684Written as ABT-263
- A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmActive, not recruitingPhase 1AbbVieNCT04041050Written as Navitoclax
- Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT02143401Written as Navitoclax
- Combination of Olaparib and Navitoclax in Women with HGSC and TNBCActive, not recruitingPhase 1Sunnybrook Health Sciences CentreNCT05358639Written as Navitoclax
- Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung CancerCompletedPhase 1National Cancer Institute (NCI)NCT02520778Written as Navitoclax
- Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell LymphomaActive, not recruitingPhase 2Peter MacCallum Cancer Centre, AustraliaNCT05864742Written as Navitoclax
- HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesWithdrawnPhase 1/2Princess Maxima Center for Pediatric OncologyNCT05740449Written as Navitoclax
- Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)WithdrawnPhase 2National Cancer Institute (NCI)NCT06210750Written as Navitoclax
- Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid TumorsTerminatedPhase 1/2National Cancer Institute (NCI)NCT03366103Written as Navitoclax
- Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With MyelofibrosisTerminatedPhase 1AbbVieNCT04480086Written as Navitoclax
- A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedPhase 1/2AbbVieNCT00481091Written as ABT-263
See all 38 studies that test navitoclax →
Given in every arm · 5 — navitoclax is usual care beside what is tested
- Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and NavitoclaxActive, not recruitingPhase 1/2St. Jude Children's Research HospitalNCT05192889Written as Navitoclax
- A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With MyelofibrosisCompletedPhase 2AbbVieNCT03222609Written as Navitoclax
- Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid LeukemiaWithdrawnPhase 1Medical College of WisconsinNCT06007911Written as Navitoclax Dose Level -1
- Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate CancerTerminatedPhase 2Rutgers, The State University of New JerseyNCT01828476Written as ABT-263
- Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedPhase 1AbbVie (prior sponsor, Abbott)NCT00868413Written as ABT-263
Codes
What other systems call navitoclax · ClinicalTrials.gg INT005266
- MeSH (NLM) C528561navitoclaxConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) XKJ5VVK2WDNAVITOCLAXConfirmed FDA, NLM, Wikidata
- Wikidata Q18002993navitoclaxConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C64776NavitoclaxOne source FDA
- DrugBank DB12340One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C528561 | navitoclax | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | XKJ5VVK2WD | NAVITOCLAX | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q18002993 | navitoclax | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C64776 | Navitoclax | One source FDA |
| DrugBank | DB12340 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.